Department of Obstetrics and Gynecology,
Section of Gynecologic Oncology,
Department of Obstetrics and Gynecology, Section of Gynecologic Oncology
Hilary Kenny has not added Biography.
If you are Hilary Kenny and would like to personalize this page please email our Author Liaison for assistance.
Ovarian follicle development requires Smad3.
Molecular endocrinology (Baltimore, Md.) Sep, 2004 | Pubmed ID: 15192076
Follicle size class contributes to distinct secretion patterns of inhibin isoforms during the rat estrous cycle.
Endocrinology Jan, 2006 | Pubmed ID: 16195413
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.
Cancer research Feb, 2007 | Pubmed ID: 17308108
Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum.
International journal of cancer. Journal international du cancer Oct, 2007 | Pubmed ID: 17546601
Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface.
The Journal of biological chemistry Feb, 2008 | Pubmed ID: 18048360
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.
The Journal of clinical investigation Apr, 2008 | Pubmed ID: 18340378
Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.
Cancer research Apr, 2008 | Pubmed ID: 18381440
MMP-2 functions as an early response protein in ovarian cancer metastasis.
Cell cycle (Georgetown, Tex.) Mar, 2009 | Pubmed ID: 19221481
Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis.
Cancer treatment and research , 2009 | Pubmed ID: 19763444
{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer.
The American journal of pathology Nov, 2009 | Pubmed ID: 19808644
Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.
Clinical cancer research : an official journal of the American Association for Cancer Research Feb, 2011 | Pubmed ID: 21149615
The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer.
Cancer discovery Jul, 2011 | Pubmed ID: 22013555
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.
Nature medicine , 2011 | Pubmed ID: 22037646
Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy.
Molecular cancer therapeutics Dec, 2013 | Pubmed ID: 24061648
Three-dimensional modeling of ovarian cancer.
Advanced drug delivery reviews Dec, 2014 | Pubmed ID: 25034878
Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.
The Journal of clinical investigation Oct, 2014 | Pubmed ID: 25202979
Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.
Nature communications , 2015 | Pubmed ID: 25653139
Molecular pathways: trafficking of metabolic resources in the tumor microenvironment.
Clinical cancer research : an official journal of the American Association for Cancer Research Feb, 2015 | Pubmed ID: 25691772
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。